| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02124746 | Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis|Polycythemia Vera|Essential Thrombocythemia | Drug: Momelotinib | Gilead Sciences | Phase 2 | 2014-04-01 | 2017-02-28 |
| NCT01998828 | Polycythemia Vera|Essential Thrombocythemia | Drug: Momelotinib | Gilead Sciences | Phase 2 | 2014-02-01 | 2016-04-26 |
| NCT02101268 | Primary Myelofibrosis (PMF)|Post-polycythemia Vera (Post-PV)|Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Drug: Momelotinib|Drug: Best Available Therapy (BAT) | Gilead Sciences | Phase 3 | 2014-06-01 | 2017-02-13 |
| NCT01969838 | Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis | Drug: Momelotinib|Drug: Ruxolitinib|Drug: Placebo to match momelotinib|Drug: Placebo to match ruxolitinib | Gilead Sciences | Phase 3 | 2013-12-01 | 2017-01-05 |
| NCT02101021 | Metastatic Pancreatic Ductal Adenocarcinoma | Drug: Momelotinib|Drug: Placebo to match momelotinib|Drug: Nab-paclitaxel|Drug: Gemcitabine | Gilead Sciences | Phase 3 | 2014-06-02 | 2017-03-21 |
| NCT01423058 | Primary Myelofibrosis|Post-Polycythemia Vera|Post-Essential Thrombocythemia Myelofibrosis | Drug: Momelotinib | Gilead Sciences | Phase 1|Phase 2 | 2011-08-01 | 2015-01-16 |
| NCT02515630 | Primary Myelofibrosis (PMF)|Post-polycythemia Vera (Post-PV) Myelofibrosis|Postessential Thrombocythemia (Post-ET) Myelofibrosis | Drug: MMB | Gilead Sciences | Phase 2 | 2016-01-29 | 2017-02-16 |
| NCT02244489 | Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma | Drug: MMB|Drug: Capecitabine|Drug: Oxaliplatin | Gilead Sciences | Phase 1 | 2014-11-01 | 2016-12-21 |
| NCT02258607 | Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer | Drug: MMB|Drug: Trametinib | Gilead Sciences | Phase 1 | 2015-03-01 | 2016-08-04 |
| NCT02206763 | EGFR Mutated EGFR TKI Naive Metastatic NSCLC | Drug: MMB|Drug: Erlotinib | Gilead Sciences | Phase 1 | 2014-10-16 | 2017-03-20 |
| NCT01236638 | Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis | Drug: Momelotinib | Gilead Sciences | Phase 2 | 2010-11-01 | 2014-07-11 |
| NCT02251821 | Primary Myelofibrosis|Secondary Myelofibrosis | Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Busulfan|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Drug: Methotrexate|Drug: Momelotinib|Drug: Mycophenolate Mofetil|Drug: Pacritinib|Drug: Ruxolitinib|Drug: Tacrolimus|Radiation: Total-Body Irradiation|Procedure: Umbilical Cord Blood Transplantation | Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 2014-10-01 | 2016-11-29 |
